Melanotan II

WHAT IT IS

Melanotan II is a lab-synthesized cyclic peptide analog of alpha-MSH, designed in the 1990s at the University of Arizona originally to explore sunless tanning. Its cyclic structure and broader receptor activity distinguish it from the linear afamelanotide molecule.

It is not sold as an approved medication in any market. Products marketed online as Melanotan II are unregulated research chemicals or gray-market injectables, not pharmaceutical-grade compounds, and their purity and identity cannot be verified without independent laboratory testing.

Its melanocortin-4 receptor activity, which influences sexual arousal pathways, led researchers to develop a related but chemically distinct molecule, bremelanotide, which was later refined and approved by the FDA as Vyleesi for hypoactive sexual desire disorder in premenopausal women. That approval belongs to bremelanotide, not to Melanotan II itself.

RESEARCHED AREAS OF INTEREST

Melanotan II has been studied, mostly in small or early-phase settings, for:

• Skin pigmentation and tanning without UV exposure, via MC1R activation
• Sexual arousal and erectile response in small human pharmacology studies, via MC4R activation
• Appetite and energy balance effects observed in some MC4R-focused animal research
• As a research tool for understanding melanocortin receptor pharmacology more broadly

PROPOSED BIOLOGICAL MECHANISM

Melanotan II is a non-selective melanocortin receptor agonist, meaning it activates MC1R, MC3R and MC4R rather than a single receptor subtype. MC1R activation on melanocytes drives eumelanin production and skin darkening.

MC4R activation, largely in the central nervous system, is linked to appetite regulation and sexual arousal pathways, which is the pharmacological basis for the erectile and libido effects some early studies and user reports describe.

Because Melanotan II hits multiple receptors rather than one, its effects are broader but less selective than either afamelanotide (mostly MC1R) or bremelanotide (engineered for a narrower profile), which is part of why it was not the molecule regulators ultimately approved.

AREAS OF ONGOING INTEREST

• Whether a more selective analog could separate pigmentation and sexual arousal effects for distinct therapeutic use
• Long-term safety of repeated non-selective melanocortin receptor activation
• The prevalence and character of adverse effects reported from unregulated Melanotan II products
• Comparative pharmacology between Melanotan II, afamelanotide and bremelanotide

WHAT THE EVIDENCE CURRENTLY SUGGESTS

Early human pharmacology studies from the 1990s and 2000s documented that Melanotan II can produce tanning and can trigger erectile responses in men, which is genuine early evidence, but these were small, short studies, not the large controlled trials that support an approved drug.

Case reports and health agency communications have also documented adverse effects associated with unregulated Melanotan II use, including nausea, flushing, spontaneous erections, darkening or changes in moles, and rare reports of new melanocytic lesions, which is a meaningful safety signal given the lack of quality control in products sold outside pharmacies.

FDA status: Melanotan II has never been approved by the FDA or any other major regulator for any human use, and the FDA has issued public warnings about unapproved Melanotan tanning products.